BCL2 and Thrombocytopenia: However, once in clinical trials, the orally bioavailable BCL-2/BCL-xL antagonist ABT-263 (Navitoclax) was found to have dose-limiting toxicity of thrombocytopenia, as a result of the induction of platelet death.